FDA Approves New ORAL Cancer Tx – Welireg
Last week the FDA approved a new ORAL therapy, Welireg (belzutifan) from Merck, for adult patients with von Hippel-Lindau (VHL) disease who require therapy for
August 19, 2021
Last week the FDA approved a new ORAL therapy, Welireg (belzutifan) from Merck, for adult patients with von Hippel-Lindau (VHL) disease who require therapy for
If you have made healthcare a career then you are likely to be familiar with NCQA. They’ve been around since the early 1990s measuring and
Now here’s something ya don’t see every day….. a leading accreditation body cutting a deal to offer a discount on specialty pharmacy accreditation. Yes, URAC
Last week the FDA approved a new, INFUSED enzyme replacement therapy, Nexviazyme (avalglucosidase alfa-ngpt) from Genzyme, indicated to treat patients 1 year of age and
It was way back in March of 2015 when the first biosimilar was approved. There was much consternation over the impact that biosimilars would have
The FDA recently approved a new therapy, Saphnelo (anifrolumab-fnia) from AstraZeneca, as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard
The FDA recently approved a new ORAL therapy, Bylvay (odevixibat) from Albireo Pharma, with an indication for treating pruritus in all subtypes of progressive familial
One of my favorite topics…. Hospitals and health systems opening their own specialty pharmacies (HSSPs). We’ve written about this growing trend for several years, but
The FDA recently approved a new ORAL therapy, Rezurock (belumosudil) from Kadmon Pharmaceuticals, with an indication for adult and pediatric patients with chronic graft-versus-host disease
We’ve often written about the legal pitfalls that specialty pharmacies may encounter that end up costing them financially (HIPAA violations are top of mind). Today
